Brenetafusp not checked

Immunocore Ltd · IMC-F106C

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Soluble PRAME-specific T cell receptor with anti-CD3 scFV concentrate for solution for intravenous (IV) infusion at a unit dose of 0.2 mg/mL.”In the company’s words, NCT06112314 on ClinicalTrials.gov
Tested for
Advanced Melanoma, Select Advanced Solid Tumors
Main trialPhase 3
“This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.”In the company’s words, NCT06112314 on ClinicalTrials.gov
Other names
IMC-F106C

Other drugs for Advanced Melanoma

All 196 drugs for Advanced Melanoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 16 Oct 2027 IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 1/2Active, not recruiting Oct 2026 Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Brenetafusp

Following is part of Solo: you see every change to Brenetafusp the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in